Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIT-AIR: Symbicort Strategies in Mild Asthma
NCT06568445Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide in asthma (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Forced Expiratory Volume in the first second at 4 weeks. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06568445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568445.